Digoxin
Digoxin, Lanoxin (digoxin) is a small molecule pharmaceutical. Digoxin was first approved as Lanoxin on 1982-01-01. It is used to treat anxiety disorders, atrial fibrillation, atrial flutter, cardiogenic shock, and heart failure amongst others in the USA. The pharmaceutical is active against sodium/potassium-transporting ATPase subunit alpha-1. In addition, it is known to target solute carrier organic anion transporter family member 4C1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Digoxin, Lanoxin (discontinued: Digoxin, Lanoxicaps, Lanoxin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Digoxin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LANOXIN | ADVANZ PHARMA | N-020405 RX | 1997-09-30 | 3 products, RLD, RS |
| LANOXIN | Covis Pharma | N-009330 RX | 1982-01-01 | 1 products, RLD, RS |
| LANOXIN PEDIATRIC | Covis Pharma | N-009330 RX | 1982-01-01 | 1 products, RLD, RS |
| DIGOXIN | Hikma Pharmaceuticals | N-021648 RX | 2004-08-26 | 1 products, RLD, RS |
Show 2 discontinued
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
272 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 74 | — | — | 1 | — | 75 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 2 | — | 6 | 10 | 22 | 40 |
| Heart failure | D006333 | EFO_0003144 | I50 | 3 | 3 | 4 | 9 | 13 | 31 |
| Atrial flutter | D001282 | EFO_0003911 | — | — | — | 2 | 2 | — | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | 1 | 1 | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | 1 | 2 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | 1 | 1 | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | 1 | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | — | — | 1 | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 3 | — | 3 | 6 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | 2 | — | 2 | 5 |
| Supraventricular tachycardia | D013617 | — | I47.1 | — | — | 2 | — | 1 | 3 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | 2 | 1 | — | — | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | 1 | — | — | 1 |
| Critical illness | D016638 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 9 | 1 | — | — | — | 10 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 2 | — | — | — | 5 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 4 | 1 | — | — | — | 5 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 3 | 1 | — | — | — | 4 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 3 | 1 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | — | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 2 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 2 | 1 | — | — | — | 2 |
Show 27 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | — | — | — | — | 11 |
| Drug interactions | D004347 | — | — | 9 | — | — | — | — | 9 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | — | — | — | — | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 4 | — | — | — | — | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | — | — | — | — | 4 |
| Overweight | D050177 | — | E66.3 | 4 | — | — | — | — | 4 |
| Melanoma | D008545 | — | — | 3 | — | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | — | 3 |
| Hepatitis c | D006526 | — | B19.2 | 2 | — | — | — | — | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 2 | — | — | — | — | 2 |
Show 44 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Induced abortion | D000028 | — | — | — | — | — | — | 3 | 3 |
| Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 2 | 2 |
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 2 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 2 | 2 |
| Sick sinus syndrome | D012804 | EFO_0004275 | I49.5 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
| Heart murmurs | D006337 | — | R01.0 | — | — | — | — | 1 | 1 |
| Rheumatic heart disease | D012214 | EFO_1001161 | I09.9 | — | — | — | — | 1 | 1 |
| Aneurysm | D000783 | — | I72.9 | — | — | — | — | 1 | 1 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Digoxin |
| INN | digoxin |
| Description | Digoxin is a cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. It has a role as an epitope, an anti-arrhythmia drug, a cardiotonic drug and an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a cardenolide glycoside and a steroid saponin. It is a conjugate acid of a digoxin(1-). |
| Classification | Small molecule |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 20830-75-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1751 |
| ChEBI ID | 4551 |
| PubChem CID | 2724385 |
| DrugBank | DB00390 |
| UNII ID | 73K4184T59 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Digoxin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 34,303 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,320 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use